BIOAF (BIOAF) Stock Price & Analysis
BIOAF (BIOAF) rose 0.00% to USD 0 as of June 10, 2026 at 03:31 UTC, according to Nexqual real-time market data.
BIOAF last closed at USD 0; the session ranged USD 0–0 on volume of 72,935 shares. Market capitalization is $7,941, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 03:31 UTC.
Key Statistics (as of June 10, 2026 at 03:31 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 72,935 shares |
| Market Cap | $7,941 |
| Exchange | PNK |
Technical Analysis (BIOAF)
Nexqual's technical model rates BIOAF "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:31 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (BIOAF)
Wall Street analysts rate BIOAF "None", per Nexqual as of June 10, 2026 at 03:31 UTC.
| Consensus Rating | None |
|---|
Earnings (BIOAF)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2022-11-30 | USD -0.01 vs est -0.01 ▲ beat |
| 2022-02-28 | USD -0.01 vs est -0.02 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:31 UTC.
Financials & Fundamentals (BIOAF)
| Total Revenue | $269,376 |
|---|---|
| Revenue Growth (YoY) | +294.80% |
| Gross Margin | -259.66% |
| Operating Margin | -469.24% |
| Profit Margin | +0.00% |
| Current Ratio | 0.11 |
| Total Cash | $156,515 |
| Total Debt | $2.21M |
| Free Cash Flow | $-310,482 |
Source: Nexqual, June 10, 2026 at 03:31 UTC.
Financial Health Score (BIOAF)
Nexqual rates BIOAF's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:31 UTC.
| Growth | Critical — Revenue -99% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $157K cash vs $2M debt |
| Cash Flow | Weak — FCF negative: -$310K, burning cash |
| Efficiency | Mixed — No data |
Ownership (BIOAF)
| Insider Ownership | +2.05% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 79.41M |
| Float | 78.07M |
Source: Nexqual, June 10, 2026 at 03:31 UTC.
Leadership (BIOAF)
BIOAF is led by Deborah Ann Rathjen B.Sc. (Hons.), FTSE, M.A.I.C.D., Ph.D., Q.C. (age 67), CEO & President, per Nexqual as of June 10, 2026 at 03:31 UTC.
| CEO & President | Deborah Ann Rathjen B.Sc. (Hons.), FTSE, M.A.I.C.D., Ph.D., Q.C. (age 67) |
|---|---|
| Chief Financial Officer | David P. Jenkins (age 63) |
| Director of Investor Relations | Graeme Dick |
| Director of Marketing | Aaron Elton |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MMND | Mastermind, Inc. | USD 0 | ▲ 0% |
| PACV | Pacific Ventures Group Inc. | USD 0 | ▲ 0% |
| EAWD | Energy and Water Development Co | USD 0.01 | ▲ 0% |
| AOXG | Aoxing Pharmaceutical Company, | USD 0 | ▼ 19.23% |
| BIXT | Bioxytran, Inc. | USD 0.03 | ▼ 1.62% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:31 UTC. This page is informational and not investment advice.